alteplase – Medxy AI

Bridging IV Alteplase Before EVT Modestly Raises Intracranial Hemorrhage Risk — But Net Clinical Impact Is Complex

By MedXY 12/11/2025

An IPD meta-analysis of six randomized trials (2313 patients) found IV alteplase before EVT modestly increased intracranial hemorrhage—particularly parenchymal hematoma—yet ICH risk must be balanced against IVT-associated improvements in reperfusion and potential clinical benefit.

Neurology news

Evaluating Alteplase Use in Minor Ischemic Stroke: Insights from a Nationwide Chinese Registry

By MedXY 10/29/2025

A nationwide Chinese registry analysis reveals no overall benefit of intravenous alteplase in minor ischemic stroke but suggests select subgroups, especially those with disabling symptoms or higher NIHSS scores, may experience improved functional outcomes.

Ophthalmology Specialties

Intravenous Alteplase Versus Oral Aspirin in Acute Central Retinal Artery Occlusion: Insights from the THEIA Phase 3 Trial and Contextual Evidence

By MedXY 10/22/2025

THEIA trial evaluated intravenous alteplase against oral aspirin in acute CRAO within 4.5 hours; no significant visual improvement difference was found, emphasizing the need for further research and meta-analyses to clarify thrombolysis benefits.

Neurology news Specialties

Extending the Therapeutic Window: Alteplase Use 4.5 to 24 Hours After Ischemic Stroke in the HOPE Trial

By MedXY 09/03/2025

The HOPE trial demonstrates that intravenous alteplase administered 4.5 to 24 hours after ischemic stroke onset improves functional independence in patients with salvageable brain tissue, despite increased risk of symptomatic intracranial hemorrhage.

Clinical Updates Neurology news Specialties

JAMA: Extending Intravenous Alteplase to 24 Hours in Imaging‑Selected Ischemic Stroke (HOPE Trial)

By MedXY 08/10/2025

The HOPE randomized trial shows that CT‑perfusion–selected patients treated with intravenous alteplase at 4.5–24 hours (no planned thrombectomy) had higher 90‑day functional independence (40.3% vs 26.3%), with increased symptomatic intracranial hemorrhage but no higher mortality.